Moleculin Biotech, Inc. (MBRX) Financials

MBRX Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 21.1 million 9.5 million
March 31, 2026 23.4 million 8.2 million
Dec. 31, 2025 22.1 million 7.1 million
Sept. 30, 2025 20.4 million 47.3 million

MBRX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -6.7 million 436000
March 31, 2026 -6.1 million 380000
Dec. 31, 2025 -5.4 million 459000
Sept. 30, 2025 -7.2 million 303000

MBRX Net Income

No data available :(

MBRX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 7.3 million - 147000
March 31, 2026 10.3 million 185000 141000
Dec. 31, 2025 8.9 million - 222000
Sept. 30, 2025 6.7 million - 258000

MBRX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 5.7 million
March 31, 2026 4.1 million
Dec. 31, 2025 3.2 million
Sept. 30, 2025 1.5 million

MBRX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 5.5 million 2.1 million -
March 31, 2026 - 5.4 million 2.5 million -
Dec. 31, 2025 - 5.1 million 2.4 million -
Sept. 30, 2025 - 3.7 million 2.1 million -

MBRX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - 8000
Dec. 31, 2025 - 9000
Sept. 30, 2025 - 21000

MBRX

Price: $6.19

52 week price:
0.16
15.75

Earnings Per Share: -16.16 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 14187

Ebitda: -2.9 million

Market Capitalization: 2.6 million

Links: